Your browser doesn't support javascript.
loading
Tislelizumab plus chemotherapy for patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy.
Zhong, Hua; Zhang, Xueyan; Tian, Panwen; Chu, Tianqing; Guo, Qisen; Yu, Xinmin; Yu, Zhuang; Li, Yalun; Chen, Lijuan; Liu, Jie; Zhang, Yan; Guan, Yan; Shi, Xun; Wang, Jing; Zhao, Yanqiu; Han, Baohui.
Afiliação
  • Zhong H; Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Zhang X; Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Tian P; Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Chu T; Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Guo Q; Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Yu X; Department of Respiratory Oncology, Shandong Cancer Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
  • Yu Z; Department of Medical Oncology, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
  • Li Y; Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
  • Chen L; Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Liu J; Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Zhang Y; Department of Oncology, The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou, Henan, China.
  • Guan Y; Department of Oncology, The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou, Henan, China.
  • Shi X; Phase I Clinical Trials Center, Shandong Cancer Hospital Afiliated to Shandong First Medical University, Jinan, Shandong, China.
  • Wang J; Department of Respiratory Oncology, Shandong Cancer Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
  • Zhao Y; Department of Medical Oncology, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
  • Han B; Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
J Immunother Cancer ; 11(8)2023 08.
Article em En | MEDLINE | ID: mdl-37597849
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Idioma: En Ano de publicação: 2023 Tipo de documento: Article